China bribery scandal snares Sino Biopharm

The Chinese said they wouldn't ignore home-grown corruption in pharma. Now, that promise is fulfilled. State-owned television network CCTV broadcast bribery allegations against a unit of Sino Biopharmaceutical, saying the company sent doctors on vacations abroad to boost sales of its drugs. Meanwhile, a smaller, privately held drugmaker, Gan & Lee Pharmaceuticals, says it's looking into allegations that it spent 800 million yuan ($130.7 million) to bribe doctors over a 5-year period, Reuters reports. Story

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.